Akarca-Dizakar Saadet Özen, Demirel Mürşide Ayşe, Coşkun Akçay Neslihan, Sipahi Mehmet, Karakoç Sökmensüer Lale, Boyunaga Hakan, Köylü Ayse, Ömeroğlu Suna
Department of Histology and Embryology, İzmir Bakırçay University Faculty of Medicine, İzmir, Turkey.
Laboratory Animals Breeding and Experimental Researches Center, Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy Gazi University, Ankara, Turkey.
J Obstet Gynaecol. 2022 Oct;42(7):3290-3298. doi: 10.1080/01443615.2022.2114322. Epub 2022 Sep 1.
The aim of this study was to evaluate the effects of coenzyme Q10 in the treatment of endometriosis rat models. Twenty seven Sprague Dawley rats were divided into four groups; Control Group ( = 7; Endometriosis group), Reference Group ( = 6; Endometriosis + Buserelin acetate, 20 mg/kg), CoQ10 Group-I ( = 7; Endometriosis + CoQ10, 50 mg/kg) and CoQ10 Group-II ( = 7; Endometriosis + CoQ10, 100 mg/kg). At the end of the experiment, all the rats were sacrificed, and the volume and histoarchitecture of endometrial implants were evaluated. The mast cells were determined by Toluidine blue and collagen fiber density was analysed by Masson's Trichrome staining. Tumour necrosis factor and vascular endothelial growth factor (VEGF) levels were analysed by enzyme-linked immunosorbent assay in peritoneal fluid and VEGF and matrix metalloproteinase-9 (MMP-9) were evaluated by immunohistochemistry. Terminal deoxynucleotidil transferase-mediated dUTP Nick end labelling (TUNEL) was also used for the detection of apoptotic cells. The CoQ10 treatment significantly decreased the volume of endometriotic implants, VEGF, and MMP-9 immunoreactivity and increased TUNEL-positive cells. The findings of the study suggest that CoQ10 can be used in endometriosis treatment by suppressing the endometriotic implants.IMPACT STATEMENT Endometriosis is a gynaecological disorder and previous studies have shown that different treatments with antioxidants cause significant regression in the endometriotic implants. In this study, CoQ10 reduced intra-abdominal adhesion scores and volume of the endometriotic implants. In addition, CoQ10 treatment affected mast cell, TNF-α, VEGF, and MMP-9. CoQ10 treatments may be possible to apply, it can contribute to science in terms of a new therapeutic treatment for endometriosis. Further studies are required to evaluate the Coenzyme Q10's effects on pain and subfertility in endometriosis.
本研究旨在评估辅酶Q10对子宫内膜异位症大鼠模型的治疗效果。将27只Sprague Dawley大鼠分为四组:对照组(n = 7;子宫内膜异位症组)、参考组(n = 6;子宫内膜异位症+醋酸布舍瑞林,20 mg/kg)、辅酶Q10-I组(n = 7;子宫内膜异位症+辅酶Q10,50 mg/kg)和辅酶Q10-II组(n = 7;子宫内膜异位症+辅酶Q10,100 mg/kg)。实验结束时,处死所有大鼠,评估子宫内膜异位种植体的体积和组织结构。用甲苯胺蓝测定肥大细胞,用Masson三色染色分析胶原纤维密度。通过酶联免疫吸附测定法分析腹腔液中的肿瘤坏死因子和血管内皮生长因子(VEGF)水平,通过免疫组织化学评估VEGF和基质金属蛋白酶-9(MMP-9)。末端脱氧核苷酸转移酶介导的dUTP缺口末端标记法(TUNEL)也用于检测凋亡细胞。辅酶Q10治疗显著降低了子宫内膜异位种植体的体积、VEGF和MMP-9免疫反应性,并增加了TUNEL阳性细胞。研究结果表明,辅酶Q10可通过抑制子宫内膜异位种植体用于子宫内膜异位症的治疗。影响声明子宫内膜异位症是一种妇科疾病,先前的研究表明,用抗氧化剂进行不同治疗可使子宫内膜异位种植体显著消退。在本研究中,辅酶Q10降低了腹腔粘连评分和子宫内膜异位种植体的体积。此外,辅酶Q10治疗影响肥大细胞、TNF-α、VEGF和MMP-9。辅酶Q10治疗可能具有应用价值,它可为子宫内膜异位症的新治疗方法提供科学依据。需要进一步研究来评估辅酶Q10对子宫内膜异位症疼痛和生育力低下的影响。